We developed a novel immunohistochemical panel to assess prognostic outcomes and treatment sensitivity by detecting the expression of VCAN, CD3G, C1QB, CD68, CD4, and CD8 in both the TME and tumor cells of 190 DLBCL patients. Here, C1QB is linked to diffuse large B-cell lymphoma.